WO2000061806A3 - GENERIC cDNA OR PROTEIN ARRAY FOR CUSTOMIZED ASSAYS - Google Patents

GENERIC cDNA OR PROTEIN ARRAY FOR CUSTOMIZED ASSAYS Download PDF

Info

Publication number
WO2000061806A3
WO2000061806A3 PCT/US2000/008611 US0008611W WO0061806A3 WO 2000061806 A3 WO2000061806 A3 WO 2000061806A3 US 0008611 W US0008611 W US 0008611W WO 0061806 A3 WO0061806 A3 WO 0061806A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecule
capture
support surface
solid support
cdna
Prior art date
Application number
PCT/US2000/008611
Other languages
French (fr)
Other versions
WO2000061806A2 (en
Inventor
Thomas M Baer
Ann Bennett Lossing
Steven T Kunitake
Original Assignee
Arcturus Eng Inc
Thomas M Baer
Ann Bennett Lossing
Steven T Kunitake
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcturus Eng Inc, Thomas M Baer, Ann Bennett Lossing, Steven T Kunitake filed Critical Arcturus Eng Inc
Priority to EP00919976A priority Critical patent/EP1183387A2/en
Priority to AU40581/00A priority patent/AU4058100A/en
Publication of WO2000061806A2 publication Critical patent/WO2000061806A2/en
Publication of WO2000061806A3 publication Critical patent/WO2000061806A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Systems and methods are described for concurrent quantification of multiple macromolecules in a flexible device. The device includes a capture location on a solid support surface. The capture location includes a capture molecule linked to the solid support surface by a first bond type. A first complexing agent including (i) a probe molecule capable of specifically binding a target molecule and (ii) a linker molecule linked by a second bond type to the probe molecule is used, such that the linker molecule can be specifically bound to the capture molecule thereby immobilizing the probe molecule on the solid support surface. The systems and methods provide advantages by allowing a user to create an array of capture locations for the concurrent quantitation of multiple macromolecules, including nucleic acids and proteins. A kit is also described, including reagents capable of linking the linker molecule to a probe molecule.
PCT/US2000/008611 1999-04-09 2000-03-31 GENERIC cDNA OR PROTEIN ARRAY FOR CUSTOMIZED ASSAYS WO2000061806A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00919976A EP1183387A2 (en) 1999-04-09 2000-03-31 GENERIC cDNA OR PROTEIN ARRAY FOR CUSTOMIZED ASSAYS
AU40581/00A AU4058100A (en) 1999-04-09 2000-03-31 Generic cdna or protein array for customized assays

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12857899P 1999-04-09 1999-04-09
US60/128,578 1999-04-09
US53886200A 2000-03-29 2000-03-29
US09/538,862 2000-03-29

Publications (2)

Publication Number Publication Date
WO2000061806A2 WO2000061806A2 (en) 2000-10-19
WO2000061806A3 true WO2000061806A3 (en) 2001-12-20

Family

ID=26826721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008611 WO2000061806A2 (en) 1999-04-09 2000-03-31 GENERIC cDNA OR PROTEIN ARRAY FOR CUSTOMIZED ASSAYS

Country Status (3)

Country Link
EP (1) EP1183387A2 (en)
AU (1) AU4058100A (en)
WO (1) WO2000061806A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
US9261460B2 (en) 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
US9353405B2 (en) 2002-03-12 2016-05-31 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016836D0 (en) 2000-07-07 2000-08-30 Lee Helen Improved dipstick assays (1)
US9777312B2 (en) 2001-06-30 2017-10-03 Enzo Life Sciences, Inc. Dual polarity analysis of nucleic acids
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
AU2002328897A1 (en) * 2001-07-13 2003-01-29 Custos Biotechnologie Gmbh Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours
US8110351B2 (en) * 2002-01-16 2012-02-07 Invitrogen Dynal As Method for isolating nucleic acids and protein from a single sample
KR100690948B1 (en) 2004-06-17 2007-03-09 한국과학기술원 Method for Cell Surface Display of Target Proteins Using FadL of E. coli
KR100784261B1 (en) 2006-01-02 2007-12-11 한국과학기술원 Method for Cell Surface Displaying of Target Proteins Using Bacillus anthracis Exosporium
CN104830812B (en) 2009-03-16 2017-09-05 盘古生物制药有限公司 Composition and method comprising the Histidyl-tRNA-synthetase splicing variants with non-classical bioactivity
WO2010120509A2 (en) 2009-03-31 2010-10-21 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US9598734B2 (en) 2010-04-29 2017-03-21 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
JP6008841B2 (en) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of methionyl tRNA synthetase
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CA2799480C (en) 2010-05-17 2020-12-15 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
US8962560B2 (en) 2010-06-01 2015-02-24 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
CN103118695B (en) 2010-07-12 2016-08-03 Atyr医药公司 The discovery for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Glycyl-tRNA synthetase
EP2608801B1 (en) 2010-08-25 2019-08-21 aTyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
CN103930563B (en) 2011-06-01 2016-11-09 医学预后研究所 For the method and apparatus predicting cancer return
ES2652136T3 (en) 2012-02-16 2018-01-31 Atyr Pharma, Inc. Histidyl-tRNA synthetases to treat autoimmune and inflammatory diseases
CA2892822C (en) 2012-11-27 2023-08-08 Pontificia Universidad Catolica De Chile Compositions and methods for diagnosing thyroid tumors
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
US11214836B2 (en) 2014-07-15 2022-01-04 Ontario Institute For Cancer Research Methods and devices for predicting anthracycline treatment efficacy

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2235689A (en) * 1989-09-06 1991-03-13 Ici Plc Amplification of a target nucleotide sequence
WO1993025563A1 (en) * 1992-06-17 1993-12-23 City Of Hope A method of detecting and discriminating between nucleic acid sequences
EP0698792A1 (en) * 1993-05-10 1996-02-28 Nissui Pharmaceutical Co., Ltd. Method for assaying more than one immunological ligand, and assay reagent and kit therefor
WO1997031256A2 (en) * 1996-02-09 1997-08-28 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP0846776A2 (en) * 1996-12-06 1998-06-10 Vysis, Inc. Devices and methods for detecting multiple analytes in samples
WO1998059243A1 (en) * 1997-06-24 1998-12-30 The Trustees Of Boston University High density streptavidin supports
WO1999015893A1 (en) * 1997-09-22 1999-04-01 Aventis Research & Technologies Gmbh & Co. Kg Addressable modular recognition system, production mode and use
WO1999032663A2 (en) * 1997-12-19 1999-07-01 Stephen Felder High throughput assay system
WO2000047767A1 (en) * 1999-02-11 2000-08-17 Astrazeneca Ab Oligonucleotide array and methods of use
WO2000058516A2 (en) * 1999-03-26 2000-10-05 Whitehead Institute For Biomedical Research Universal arrays

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2235689A (en) * 1989-09-06 1991-03-13 Ici Plc Amplification of a target nucleotide sequence
WO1993025563A1 (en) * 1992-06-17 1993-12-23 City Of Hope A method of detecting and discriminating between nucleic acid sequences
EP0698792A1 (en) * 1993-05-10 1996-02-28 Nissui Pharmaceutical Co., Ltd. Method for assaying more than one immunological ligand, and assay reagent and kit therefor
WO1997031256A2 (en) * 1996-02-09 1997-08-28 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP0846776A2 (en) * 1996-12-06 1998-06-10 Vysis, Inc. Devices and methods for detecting multiple analytes in samples
WO1998059243A1 (en) * 1997-06-24 1998-12-30 The Trustees Of Boston University High density streptavidin supports
WO1999015893A1 (en) * 1997-09-22 1999-04-01 Aventis Research & Technologies Gmbh & Co. Kg Addressable modular recognition system, production mode and use
WO1999032663A2 (en) * 1997-12-19 1999-07-01 Stephen Felder High throughput assay system
WO2000047767A1 (en) * 1999-02-11 2000-08-17 Astrazeneca Ab Oligonucleotide array and methods of use
WO2000058516A2 (en) * 1999-03-26 2000-10-05 Whitehead Institute For Biomedical Research Universal arrays

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NIEMEYER C M ET AL: "OLIGONUCLEOTIDE-DIRECTED SELF-ASSEMBLY OF PROTEINS: SEMISYNTHETIC DNA-STREPTAVIDIN HYBRID MOLECULES AS CONNECTORS FOR THE GENERATION OF MACROSCOPIC ARRAYS AND THE CONSTRUCTION OF SUPRAMOLECULAR BIOCONJUGATES", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 22, no. 25, 1994, pages 5530 - 5539, XP000645135, ISSN: 0305-1048 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
US9261460B2 (en) 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
US9316587B2 (en) 2002-03-12 2016-04-19 Enzo Life Sciences, Inc. Processes for quantitative or qualitative detection of single-stranded or double-stranded nucleic acids
US9353405B2 (en) 2002-03-12 2016-05-31 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes

Also Published As

Publication number Publication date
AU4058100A (en) 2000-11-14
WO2000061806A2 (en) 2000-10-19
EP1183387A2 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
WO2000061806A3 (en) GENERIC cDNA OR PROTEIN ARRAY FOR CUSTOMIZED ASSAYS
ATE401419T1 (en) IMMOBILIZATION OF UNMODIFIED NUCLEIC ACIDS ON SUBSTRATES ACTIVATED WITH ACYL FLUORIDE
ATE549414T1 (en) METHOD FOR ISOLATION OF CELLS
DK0787205T3 (en) Method for amplifying nucleic acids on a solid phase and reagent kits thereto
EP0915336A3 (en) Opposable-element chromatographic assay device for detection of analytes
CA2162568A1 (en) Method and reagent for simultaneously assaying one or more ligands in a group of preselected ligands
WO2004005477A3 (en) Protein microarrays on mirrored surfaces for performing proteomic analyses
CA2215042A1 (en) Assay reagents and devices
WO2002044327A3 (en) Method and apparatus for protein manipulation
GB2393512A (en) Use of a biochip for the diagnosis of sepsis or sepsis related syndrome
BR9811039A (en) Mammalian cytokine: interleukin-b30 and related reagents
ATE545019T1 (en) MICROFLUIDIC EXTRACTION METHOD
WO2003062402A3 (en) Use of collections of binding sites for sample profiling and other applications
DE60236361D1 (en) SORTING AND IMMOBILIZATION SYSTEM FOR NUCLEINS
CA2084492A1 (en) Multivalent dextran reagent for use in precipitation tests
EP1627038A4 (en) Microparticle based biochip systems and uses thereof
WO2001002600A3 (en) Detection of analytes using attenuated enzymes
WO2001020326A3 (en) Materials and methods for the determination of an analyte
WO2003046140A3 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
EP1403640A4 (en) Peptide-immobilized baseboard and method of assaying target protein using the same
BR0206904A (en) Methods and Devices for Glycate Protein Quantification
BRPI0416270A (en) method for detecting an analyte in a sample, and method and kit for detecting an antibody specific for a sample
WO2008094205A3 (en) A mild chemically cleavable linker system
WO2004046730A3 (en) Uses of ble proteins and antibiotics from the bleomycin family
AU2002229974A1 (en) Biochemical method and apparatus for detecting protein characteristics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2000919976

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000919976

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000919976

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP